エタンブトール

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

• 注意書き

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P330：口をすすぐこと。

エタンブトール 価格

MSDS Information

• Ethambutol

エタンブトール 化学特性,用途語,生産方法

• 解説

  エタンブトールは，結核の化学療法に用いられる薬剤の一つ。リファンピシンやイソニアジドなど他の抗結核薬と併用される。化学式C10H24N2O2　EB。小学館 デジタル大辞泉について　情報 | 凡例

• 用途

  抗結核薬二次抗結核薬

• 効能

  抗結核薬, アラビノシル転移酵素阻害薬

• 使用

  Ethambutol is an antitubercular antibiotic.

• 適応症

  Ethambutol is a water-soluble, heat-stable compound that acts by inhibition of arabinosyl transferase enzymes that are involved in cell wall biosynthesis. Nearly all strains of M. tuberculosis and M. kansasii and most strains of Mycobacterium avium-intracellulare are sensitive to ethambutol. Drug resistance relates to point mutations in the gene (EmbB) that encodes the arabinosyl transferases that are involved in mycobacterial cell wall synthesis.

• 定義

  ChEBI: An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial d ug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant str ins of M. tuberculosis are readily produced if ethambutol is used alone.

• 抗菌性

  Ethambutol is active against several species of mycobacteria and nocardiae. MICs on solid media are: M. tuberculosis 0.5–2 mg/L; M. kansasii 1–4 mg/L; other slowly growing mycobacteria 2–8 mg/L; rapidly growing pathogens 2–16 mg/L; Nocardia spp. 8–32 mg/L.
  Resistance is uncommon and is a multistep process due to mutations in the embA, embB and embC gene cluster. A mutation in codon 306 of the embB gene predisposes to the development of resistance to a range of antituberculosis agents, possibly by affecting cell-wall permeability.

• 応用例（製薬）

  A synthetic ethylenediamine derivative formulated as the dihydrochloride for oral administration. The dry powder is very soluble and stable.

• 作用機序

  The mechanism of action of EMB remains unknown, although mounting evidence suggests a specific site of action for EMB. It has been known for some time that EMB affects mycobacterial cell wall synthesis; however, the complicated nature of the mycobacterial cell wall has made pinpointing the site of action difficult. In addition to the peptidoglycan portion of the cell wall, the mycobacterium have a unique outer envelop consisting of arabinofuranose and galactose (AG), which is covalently attached to the peptidoglycan and an intercalated framework of lipoarabinomannan (LAM) . The AG portion of the cell wall is highly branched and contains distinct segments of galactan and distinct segments of arabinan. At various locations within the arabinan segments (terminal and penultimate), the mycolic acids are attached to the C-5′ position of arabinan. Initially, Takayama et al. reported that EMB inhibited the synthesis of the AG portion of the cell wall. More recently, it has been reported that EMB inhibits the enzymes arabinosyl transferase. One action of arabinosyl transferase is to catalyze the polymerization of D-arabinofuranose, leading to AG. Ethambutol mimics arabinan, resulting in a buildup of the arabinan precursor β-D-arabinofuranosyl- 1-monophosphoryldecaprenol and, as a result, a block of the synthesis of both AG and LAM. The mechanism of resistance to EMB involves a gene overexpression o

• 薬理学

  Orally administered ethambutol is well absorbed (70–80%) from the gut, and peak serum concentrations are obtained within 2 to 4 hours of drug administration; it has a half-life of 3 to 4 hours. Ethambutol is widely distributed in all body fluids, including the cerebrospinal fluid, even in the absence of inflammation.A majority of the unchanged drug is excreted in the urine within 24 hours of ingestion. Up to 15% is excreted in the urine as an aldehyde and a dicarboxylic acid metabolite. Ethambutol doses may have to be modified in patients with renal failure.

• 薬物動態学

  Oral absorption: c. 80%, but some patients absorb it poorly
  C_max 25 mg/kg oral: 2–6 mg/L after 2–3 h
  Plasma half-life: 10–15 h
  Volume of distribution: >3 L/kg
  Plasma protein binding: 20–30%
  Absorption is impeded by aluminum hydroxide and alcohol. It is concentrated in the phagolysosomes of alveolar macrophages. It does not enter the cerebrospinal fluid (CSF) in health but CSF levels of 25–40% of the plasma concentration, with considerable variation between patients, are achieved in cases of tuberculous meningitis.
  Various metabolites are produced, including dialdehyde, dicarboxylic acid and glucuronide derivatives. Around 50% is excreted unchanged in the urine, with an additional 10–15% as metabolites, and 20% is excreted unchanged in feces.

• 臨床応用

  Ethambutol has replaced aminosalicylic acid as a first-line antitubercular drug. It is commonly included as a fourth drug, along with isoniazid, pyrazinamide, and rifampin, in patients infected with MDR strains. It also is used in combination in the treatment of M. aviumintracellulare infection in AIDS patients.

• 副作用

  The major toxicity associated with ethambutol use is retrobulbar neuritis impairing visual acuity and redgreen color discrimination; this side effect is dose related and reverses slowly once the drug is discontinued. Mild GI intolerance, allergic reaction, fever, dizziness, and mental confusion are also possible. Hyperuricemia is associated with ethambutol use due to a decreased renal excretion of urates; gouty arthritis may result.

エタンブトール 上流と下流の製品情報

エタンブトール 生産企業

Global(128)Suppliers

エタンブトール スペクトルデータ(¹HNMR)

74-55-5, エタンブトール キーワード